IsoRay, Inc. (ISR)
(Delayed Data from AMEX)
$0.40 USD
+0.01 (3.62%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.41 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.40 USD
+0.01 (3.62%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.41 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 3.48% and 0.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -0.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -0.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
IsoRay (ISR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
IsoRay (ISR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Company News for May 14, 2020
by Zacks Equity Research
Companies In The News Are:
IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 4.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?